EBIT at other companies
Other financials
Where this comes from
Calculated from Palvella Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's EBIT?
- Palvella Therapeutics (PVLA) reported EBIT of -$14.86M in Q1 2026.
- How has Palvella Therapeutics's EBIT changed year-over-year?
- Palvella Therapeutics's EBIT decreased by 88.7% year-over-year, from -$7.87M to -$14.86M.
- What is the long-term trend for Palvella Therapeutics's EBIT?
- Over 2 years (2021 to 2025), Palvella Therapeutics's EBIT has grown at a -13.7% compound annual growth rate (CAGR), from -$51.83M to -$38.6M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.